报价延迟最少15分钟:2025/08/02 11:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-46.00/-3.75
|
|
企业价值
279.67M
|
| 资产负债 |
|
每股账面净值
0.05
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/02 11:50 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improvedclinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
